Articles tagged with Cancer Medication
Researchers at Duke University have developed a simple and inexpensive method for loading cancer drugs into nano-scale delivery vehicles. The new formulation showed promising results in animal models, eliminating tumors after a single treatment while reducing side effects associated with systematic chemotherapy.
A new study found that switching to a newer type of immunosuppressant drug, sirolimus, reduced the rate of skin cancer in kidney transplant patients by 25%. Nearly half of patients stopped treatment due to side effects. The researchers believe this could offer a new option for reducing skin cancer risk in transplant recipients.
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients taking anti-tumor necrosis factor (TNF) therapy did not experience an elevated cancer risk. The study included data from 6,366 patients and compared their cancer risk to those who were not taking TNF inhibitors or using other immunosuppressant drugs.
UT Southwestern researchers successfully used a combination of the investigational drug BEZ235 and low-dose radiation to eliminate non-small cell lung cancer in mice. The treatment targeted the PI3K protein pathway, which is often activated in K-RAS mutated tumors, making these cancers resistant to traditional treatments.
The university's partnership with UCLA will enhance its capability to conduct high-quality cancer research, recruit more investigators, and strengthen outreach programs. The grant will also enable the university to add students and clinical fellows as future cancer researchers.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
A consortium led by UT Health Science Center at Houston is establishing a center to conduct innovative cancer research, focusing on transport oncophysics and targeting liver cancers. Researchers aim to develop new approaches to studying cancer processes and exploiting its weaknesses to mount decisive attacks against metastatic disease.
Researchers found that statins can inhibit growth and development of cancer cells, as well as treat diabetes and neurological disorders like Parkinson's. The study used the nematode C. elegans as an ideal test subject, showing dramatic effects on enzyme activity.
Researchers identified a cellular pathway by which alcohol promotes cancer progression through the activation of EMT in colon and breast cancer cells. This mechanism may contribute to the increased risk of these cancers associated with alcohol consumption.
A Dartmouth study has found that patients taking immunosuppressive drugs such as glucocorticoids may be at higher risk of developing bladder cancer. The research examined the long-term use of glucocorticoids in 786 bladder-cancer patients and 1,083 control subjects, revealing a potential link between the two.
A study found that patients with IBD, particularly those on thiopurine medications, may be at higher risk for non-melanoma skin cancer. The study also showed that recent use of immunosuppressive medications was associated with increased risk of NMSC.
A new Johns Hopkins Engineering in Oncology Center will study physical underpinnings of cancer growth and spread, aiming to develop innovative therapies and diagnostic tools. Researchers hope to gain a better understanding of the complex forces involved in metastasis.
Researchers found that leukemia cells reliant on MCL-1 are more sensitive to chemotherapeutic drugs than those dependent on BCL-2. A block in apoptosis selected during oncogenesis can significantly impact cancer's response to chemotherapy.
A workshop conducted by the National Cancer Institute and FDA identified critical decision points in cancer biomarker and drug development. The points emphasize the importance of understanding the biology of the target and its interaction with drugs, as well as rigorous sample collection and quality control.
Researchers found that the tumour suppressor gene Pten plays a critical role in suppressing the development of breast tumors. The study used transgenic mouse models and showed that deletion of Pten in fibroblasts accelerates tumor growth, highlighting the importance of the tumor microenvironment in cancer development.
Cancer survivors often struggle with sexual dysfunction due to side effects from treatment. Internists rarely discuss these issues with patients, leaving them without proper care and support. Training is needed to prepare primary care physicians to address these concerns effectively.
Harris Wang won $25,000 for faster cell programming tool MAGE, while Stephen Diebold received a prize for improved pointing stick for people with quadriplegia. Other graduate and undergraduate winners were also announced for their top work.
UCI scientists identify protein PT as the key to making aflatoxin, a toxin produced by mold on nuts and grains that can cause liver cancer. The discovery could lead to methods of limiting its production and developing new inhibitors to prevent liver cancer.
Researchers at Georgetown University Medical Center found that a growth factor implicated in mental retardation disorders regulates dendritic spine development and spatial learning. Increasing the transport of this growth factor may be a way to treat these conditions.
A recent study published by Fox Chase Cancer Center researchers reveals that nearly a quarter of cancer survivors who still smoke have not been advised to quit by their health care providers in the last year. Health care providers are missing an opportunity to make a significant difference in the quality of life of their patients by no...
A new class of compounds containing Ruthenium and Osmium has been found to be highly effective in killing ovarian and colon cancer cells, even those resistant to Cisplatin. The discovery is a significant step forward in the field of medicinal chemistry.
A Virginia Tech chemist has received an NIH New Innovator grant to develop new heart disease and cancer medicines with improved efficacy and reduced side effects. Her team is creating carbohydrate-based polymers that can deliver genetic drugs directly to cells.
A team of international molecular scientists has discovered a fast mechanism by which cells communicate changes, such as location during cancer spread, to adjacent cells. This discovery sheds light on cell behavior and could lead to the development of new drugs for diseases like cancer, rheumatoid arthritis, and Alzheimer's disease.
Researchers are studying naturally occurring cancers in dogs to inform the development of new cancer drugs, devices, and imaging strategies for human cancer patients. The study aims to improve care for human patients by leveraging insights gained from canine cancer biology.
Researchers at UCLA's Jonsson Comprehensive Cancer Center found that the loss of PTEN tumor suppressor gene plays a central role in transforming benign neurofibromas into malignant and deadly sarcomas. The study could lead to new therapies targeting cell signaling pathways regulated by PTEN.
Researchers at the University of Pittsburgh have discovered tiny strands of RNA, previously considered 'junk,' that are actually very stable molecules with potential roles in cellular processes. The findings could lead to new types of biomarkers for diagnosis and prognosis, as well as new therapeutic targets.
A Tel Aviv University drug based on an older generation antibiotic shows promise in treating colon cancer by suppressing polyp growth and repairing genes. Preclinical studies have shown a 80% reduction in polyp size and a 30% increase in mouse lifespan.
Researchers at University Hospitals Case Medical Center found that African Americans with non-small cell lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to EGFR inhibitor drugs. The study highlights the need for personalized treatment approaches based on ethnicity and genetic variation.
A massive international study is examining potential genetic consequences of reproductive organs exposed to curative therapy by drugs or radiation. Scientists aim to determine if radiation treatment increases birth defects, stillbirths, and specific conditions like Down syndrome in offspring.
A phase 2 study found that adding imatinib mesylate to regular chemotherapy increased three-year survival rates for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) from 30-35% to 87%. The drug was well-tolerated and showed no significant side effects.
Researchers at Northwestern University discovered a potent new chemotherapy cocktail that inhibits breast cancer cell invasion by half. The mix of dasatinib and doxorubicin targets the Src kinase enzyme, believed to play a key role in breast cancer metastasis.
A new polymer has been developed that can deliver genetic cargo into cells and track its movement using luminescence and magnetic resonance imaging. This breakthrough could lead to more specific and targeted treatments for diseases such as cancer and cardiovascular disease.
A study presented at the AAO-HNSF Annual Meeting found that photodynamic therapy is effective in treating certain types of head and neck cancers. The treatment, which combines medications with a specific light therapy, can achieve organ preservation and cancer cure for superficially spread but not deeply infiltrated cancers.
A new nomogram developed by Ronald DeMatteo and colleagues predicts a patient's risk of cancer recurrence after surgery to remove primary GIST. The tool uses tumour size, location, and mitotic index as established prognostic criteria.
Recent trials have shown small reductions in prostate cancer mortality, but the potential benefits must be balanced against increased diagnosis rates and treatment complications. Developing more effective decision support tools may improve discussions between men and their physicians about screening.
Researchers identified two chemicals that correctly process essential proteins in cells, potentially leading to new treatments for cancers and neurodegenerative diseases. This breakthrough could benefit millions of people worldwide suffering from genetic disorders, including ataxia-telangiectasia and muscular dystrophy.
A Phase I clinical study by M. D. Anderson Cancer Center shows huachansu, a Chinese medicine derived from toad venom, has low toxicities even at doses eight times higher than conventional ones. The treatment slowed disease progression in some patients with liver, lung, colon and pancreatic cancer.
A new study found that investing in colorectal cancer screening programs could reduce treatment costs by more than half. The study suggests that the increasing use of expensive cancer drugs will make screening programs more cost-effective, making them a desirable investment for governments and insurance companies.
A diabetes drug has shown promising results in slowing muscle wasting and fat loss in mice with colon cancer tumors, suggesting a potential new approach to treating cachexia, a syndrome associated with severe weight loss and muscle breakdown that can lead to cancer deaths.
Recent research on five common cancers shows lifestyle interventions can prevent cancers, reduce risk factors, and counsel patients for lower cancer risk. Changes in diet, exercise, smoking habits, and UV radiation exposure can decrease cancer incidence.
Researchers at UNC are working on developing new methods to measure cellular signaling and tackle chronic pain. Dr. Joseph DeSimone is using a Pioneer Award to create new delivery methods for biological therapeutics, while Dr. Mark Zylka aims to treat pain with enzyme-based treatments. These projects have the potential to profoundly im...
A large randomized trial has found that sorafenib plus capecitabine improves the time women live without disease worsening by 74% compared to chemotherapy alone. The treatment was well-tolerated and manageable, with no new side effects observed.
Researchers at Yale University have discovered a novel mechanism that stops cancer cells from growing and dividing. The 'on-off switch' mechanism involves a tiny bit of genetic material that regulates the function of tumor-suppressor proteins, preventing cancer cells from proliferating.
A new preclinical drug test platform developed by researchers in Hamburg enables analysis of tumour tissue for individual patient drug responses on the molecular level. This allows for more accurate extrapolation of response from preclinical cell models to patients, reducing the risk of toxicity and improving clinical trial efficiency.
Expert calls for a shift in cancer research priorities, focusing on prevention and non-drug treatments to combat the growing cancer burden. The global cancer cases are expected to rise, and improving early detection and primary prevention strategies hold the potential for significant gains.
A new study found that switching post-menopausal women with early breast cancer to exemestane after two or three years of tamoxifen improves disease-free survival and overall survival. The study involved 4,724 postmenopausal women who were followed for an average of 91 months.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
Three medications effective in reducing breast cancer risk also have serious side effects, according to a new study. Tamoxifen, raloxifene, and tibolone reduce invasive breast cancer incidence but vary in their adverse effect profiles.
A new Tel Aviv University drug carrier delivers existing life-saving therapies directly to cancer tumors, reversing growth and inhibiting tumor growth by 50%. The innovative formulation targets tumors without affecting normal healthy cells, offering a potential solution for various forms of cancers and diseases.
The Baumann Lab has identified a key protein role in distinguishing chromosome ends from DNA breaks, preventing genomic instability and cancer. RAP1 plays a critical role in cancer prevention and may be linked to age-related diseases.
A Loyola University Health System study found that breast cancer patients can prevent bone loss by correcting secondary causes, such as vitamin D deficiency, and using bisphosphonate osteoporosis drugs. After one year, patients with secondary causes showed stable bone mineral density.
A study by American Cancer Society found that many breast cancer patients are not receiving targeted therapies due to lack of testing. Inaccurate HER2 test results also affect treatment choices, highlighting the need for better testing practices.
Researchers at Harvard Medical School have discovered a diabetes drug that selectively targets and kills cancer stem cells in mice, leading to faster tumor reduction and prolonged remission. The findings support the potential use of metformin as a first-line treatment in breast cancer patients.
Researchers found a diabetes drug, metformin, selectively targets and kills cancer stem cells in mice, reducing tumor growth and prolonging remission. The compound's effectiveness is attributed to its ability to work independently of insulin sensitivity improvements.
The International Conference on Endothelin presented promising results for new endothelin receptor antagonist drugs, which may benefit conditions like kidney disease and pulmonary hypertension. However, challenges in determining the best treatment approach and addressing potential side effects must be overcome.
Researchers at UCSB have developed a novel drug delivery system that uses nanoparticles and laser exposure to deliver siRNA into cancer cells, providing temporal and spatial control over gene expression. The technique has potential applications in delivering multiple drugs against diverse biological targets.
Patients who exhibited skin rash from lapatinib showed a greater tumor response and longer survival, while others experienced no benefit. The study suggests that larger trials with more responsive patients may show a definite survival benefit.
Researchers at Columbia University Medical Center found that a cancer drug can restore memory deficits in patients with Alzheimer's disease by targeting a previously unknown defect in the brain. The drug works by increasing DNA spool acetylation and gene transcription, leading to improved memory performance.
A team of researchers has identified a molecular signature that can predict which patients with aggressive cancers, such as pancreatic and breast cancer, are likely to respond to therapy with the anti-cancer drug dasatinib. The discovery could lead to personalized treatment approaches for solid tumors currently resistant to therapies.
Scientists at VCU School of Medicine have identified a new lipid mediator that regulates genes, a discovery that could lead to the development of drugs to fight cancer and inflammatory diseases. The study found that S1P acts like a histone deacetylase inhibitor, regulating gene expression in the cell nucleus.